NON-SMALL CELL LUNG CANCER

This study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a MET gene change. The goal was to see if the drug could shrink tumors. The trial was stopped early and e…

This study tested whether adding canakinumab to standard pembrolizumab plus chemotherapy could help people with advanced non-small cell lung cancer live longer or slow tumor growth. About 673 participants were enrolled, but the trial was stopped early. The approach aimed to contr…

This pilot study tested giving immunotherapy (durvalumab, with or without tremelimumab) along with standard radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part before the study was stopped early. The main goals were to check safety and wheth…

This early-phase study tested whether adding IL-12 gene therapy to the immunotherapy drug atezolizumab could help people with advanced non-small cell lung cancer whose disease had worsened after initial immunotherapy. The trial enrolled 13 adults and focused on safety and how lon…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors like ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-stage study tested a new drug (PF-07820435) alone or with another drug (sasanlimab) in 9 people with advanced solid tumors like lung, melanoma, and kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limit…

This early-stage study tested a new drug called AUR106 in 21 adults with advanced solid tumors like lung, stomach, bladder, kidney, colon, or esophageal cancer that had come back. The main goals were to find a safe dose and check for side effects. The study was stopped early, so …

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to see if the treatment was safe and to look for early signs of tumor shrinkag…

This study tested a treatment that uses a patient's own immune cells (called TIL) taken from their tumor, grown in a lab, and then given back to fight the cancer. It included 225 adults with advanced melanoma, head and neck cancer, or non-small cell lung cancer. The goal was to s…

This study aimed to see if the drug capmatinib, given before and after surgery, could improve outcomes for people with a certain type of lung cancer (non-small cell lung cancer with MET mutations). Only 4 adults took part before the trial was stopped early, so no clear conclusion…

This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…

This early-stage study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The main goals were to check safety and find the right dose. The study was stopped early, so results are limi…

This study tested a drug called tovorafenib in people aged 12 and older with advanced cancers that have specific genetic changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The trial was stopped early, so results are limited. It involved 23 participants w…

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo shrank tumors. The trial was terminated early, so results are limited. Participants had to have measur…

This study tested a combination of the immunotherapy drug durvalumab and two different types of targeted radiation for people with advanced non-small cell lung cancer. The goal was to see if the treatment improved quality of life and controlled tumor growth. The trial was stopped…

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or with other cancer drugs to see if it was safe and could shrink tumors. The study was terminated early, so results are limited.

This early-phase study tested an experimental drug (PF-07265028) alone or with another drug (sasanlimab) in 21 people with advanced solid tumors like lung, stomach, or bladder cancer. The goal was to find the safest dose and see if the drugs shrink tumors. The study was stopped e…

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against a standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that had not been treated before. The trial aimed to see if the combo could help patients live longer or slo…

This early-stage trial tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study tested a new drug called SAR444245 combined with other cancer treatments in 106 adults with advanced non-small cell lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. The trial was stopped early, so results are limited. Par…

This early-stage study tested a new drug, DCC-3116, alone or with other targeted therapies, in people with advanced solid tumors that have certain gene mutations (RAS/MAPK pathway). The goal was to find safe doses and see if the drug could shrink tumors. The study was terminated …

This study tested a new drug (HBI-8000) combined with an existing immunotherapy (pembrolizumab) in adults with advanced non-small cell lung cancer. The goal was to see if the combination was safe and tolerable. Only 5 people took part before the study was stopped early.

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in people with advanced solid tumors that have specific KRAS gene mutations. The goal was to check safety and how the body processes the drug. The study was stopped early, so results…

This study tested whether giving patients their own immune cells (lymphocytes) after chemotherapy and radiation could help restore their immune system. It included 19 adults with non-small cell lung cancer or esophageal cancer. The approach aimed to improve immune health, but the…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a potent chemotherapy directly to cancer cells. …

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This early-phase study tested a new cell therapy called ITIL-306 in adults with advanced ovarian, lung, or kidney cancers that had stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack tumors. The study aimed to check …

This study tested an experimental drug called OC-001, either by itself or together with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early, and only 73 peo…

This study looked at whether two immunotherapy drugs, ipilimumab and nivolumab, could help people with advanced non-small cell lung cancer who had not received prior treatment. Only 5 participants were enrolled before the study was stopped early. The goal was to see how well the …

This early-phase study tested an experimental drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The trial was…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested a new treatment for non-small cell lung cancer using a patient's own immune cells (TILs) combined with another drug. The goal was to see if the combination was safe and tolerable. Only 2 adults joined before the study was stopped early, so results are very limit…

This early-stage study tested a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The drug works by breaking down the faulty EGFR protein that drives cancer growth. The trial aimed to find safe doses and check for early…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise radiation therapy (SBRT) could help people with early-stage non-small cell lung cancer who cannot have surgery. About 448 adults took part, but the trial was stopped early. The goal was to…

This study tested whether the drug olaparib could help people with advanced non-small cell lung cancer that responded to initial chemotherapy. Only patients whose cancer shrank after chemotherapy were given either olaparib or a placebo as ongoing treatment. The trial was stopped …

This study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers. It included 77 adults with Merkel cell, skin, lung, breast, or throat cancer. The study was termi…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced non-small cell lung cancer that had spread. The goal was to see if these drugs could control the cancer without needing chemotherapy. Only 5 people took part before the study was stopped …

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-phase trial aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer before surgery. Only one person enrolled before the study was stopped. The main goal was to measure immune c…

This early-phase study tested a new drug, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study …

This early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-stage study tested a new drug called BT-001, injected directly into tumors, either by itself or with the immunotherapy pembrolizumab. It included 31 adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that had spread. The main goals were to c…

This study tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in people with a type of lung cancer that had spread to the brain but wasn't causing symptoms. The goal was to see if the combination could control the brain tumors and delay the…

This early-stage trial tested a new gene therapy (quaratusugene ozeplasmid) combined with an immunotherapy drug (pembrolizumab) for people with advanced non-small cell lung cancer who had already been treated. The goal was to see if the combination was safe and worked better than…

This study tested whether giving a higher radiation dose directly to the lung tumor, while keeping standard doses to surrounding areas, is safe for people with non-small cell lung cancer. Six participants received this targeted dose escalation along with chemotherapy. The goal wa…

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their c…

This study looked at the safety of giving a type of immunotherapy (pembrolizumab) either before or after targeted radiation (SABR) in people with advanced non-small cell lung cancer that had spread. Only 13 people took part before the study was stopped early. The goal was to see …

This study tested a new drug called DCC-3084, alone or with other cancer treatments, in people with advanced solid tumors that have certain gene changes (MAPK pathway). The trial aimed to find safe doses and see if the drug could shrink tumors. It was stopped early after enrollin…

This study looked at whether monitoring daily step counts in people with advanced lung cancer during chemoradiotherapy could help doctors provide better supportive care and reduce problems like hospital stays or treatment delays. Only 3 people took part before the study was stopp…

This study looked at whether a program combining different types of exercise could help people with advanced lung cancer feel less tired, move better, and have a better quality of life. It was designed for adults with stage III or metastatic non-small cell lung cancer who were al…

This study tested a mobile app called Apricity CARE to help ethnic and racial minority patients with non-small cell lung cancer report side effects from immunotherapy. The goal was to reduce treatment delays and hospital visits. The study was stopped early, but it aimed to improv…

This study followed 83 adults with advanced non-small cell lung cancer who were starting standard treatments like immunotherapy or targeted therapy. The goal was to gather information to help develop a digital tool that can spot early signs of pneumonitis, a serious lung inflamma…

This study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing.…